China Anti Hypertensive Drugs Market

ID: MRFR/HC/54830-HCR
200 Pages
Satyendra Maurya
Last Updated: March 28, 2026
China Antihypertensive Drugs Market China Antihypertensive Drugs Market Research Report: By Drug Class (Diuretics, ACE Inhibitors, Beta Blockers, Calcium Channel Blockers, Angiotensin II Receptor Antagonists), By Administration Route (Oral, Injectable, Transdermal), By Indication (Essential Hypertension, Secondary Hypertension, Hypertensive Crisis) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Forecast to 2035
China Anti Hypertensive Drugs Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)3.99%
2018 Market Size$ 6.55 Billion
2024 Market Size$ 1.88 Billion
2035 Market Size$ 2.89 Billion
Key Players
AstraZeneca
Novartis
Pfizer
Boehringer Ingelheim
Sanofi
Bristol-Myers Squibb
Trends
  • Rising Demand for Personalized Medicine
  • Increased Focus on Preventive Healthcare
  • Expansion of Digital Health Solutions
Opportunities
  • Growing Aging Population
  • Rising Healthcare Expenditure
  • Government Policies and Regulations
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 China Anti Hypertensive Drugs Market, BY Drug Class (USD Billion)
      1. 4.1.1 Angiotensin Converting Enzyme Inhibitors
      2. 4.1.2 Angiotensin II Receptor Blockers
      3. 4.1.3 Calcium Channel Blockers
      4. 4.1.4 Diuretics
      5. 4.1.5 Beta Blockers
    2. 4.2 China Anti Hypertensive Drugs Market, BY Administration Route (USD Billion)
      1. 4.2.1 Oral
      2. 4.2.2 Intravenous
      3. 4.2.3 Subcutaneous
      4. 4.2.4 Transdermal
    3. 4.3 China Anti Hypertensive Drugs Market, BY Therapeutic Area (USD Billion)
      1. 4.3.1 Hypertension
      2. 4.3.2 Heart Failure
      3. 4.3.3 Chronic Kidney Disease
      4. 4.3.4 Diabetes
    4. 4.4 China Anti Hypertensive Drugs Market, BY Patient Demographics (USD Billion)
      1. 4.4.1 Elderly
      2. 4.4.2 Adults
      3. 4.4.3 Pediatric
      4. 4.4.4 Pregnant Women
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the China Anti Hypertensive Drugs Market
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the China Anti Hypertensive Drugs Market
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 AstraZeneca (GB)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Novartis (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Pfizer (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Boehringer Ingelheim (DE)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Sanofi (FR)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Bristol-Myers Squibb (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Merck & Co. (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 GSK (GB)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Teva Pharmaceutical Industries (IL)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 CHINA MARKET ANALYSIS BY DRUG CLASS
    3. 6.3 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    4. 6.4 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA
    5. 6.5 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    6. 6.6 KEY BUYING CRITERIA OF CHINA ANTI HYPERTENSIVE DRUGS MARKET
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CHINA ANTI HYPERTENSIVE DRUGS MARKET
    9. 6.9 DRIVERS IMPACT ANALYSIS: CHINA ANTI HYPERTENSIVE DRUGS MARKET
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHINA ANTI HYPERTENSIVE DRUGS MARKET
    11. 6.11 SUPPLY / VALUE CHAIN: CHINA ANTI HYPERTENSIVE DRUGS MARKET
    12. 6.12 CHINA ANTI HYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, 2024 (% SHARE)
    13. 6.13 CHINA ANTI HYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
    14. 6.14 CHINA ANTI HYPERTENSIVE DRUGS MARKET, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
    15. 6.15 CHINA ANTI HYPERTENSIVE DRUGS MARKET, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
    16. 6.16 CHINA ANTI HYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC AREA, 2024 (% SHARE)
    17. 6.17 CHINA ANTI HYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
    18. 6.18 CHINA ANTI HYPERTENSIVE DRUGS MARKET, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    19. 6.19 CHINA ANTI HYPERTENSIVE DRUGS MARKET, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DRUG CLASS, 2026-2035 (USD Billion)
      2. 7.2.2 BY ADMINISTRATION ROUTE, 2026-2035 (USD Billion)
      3. 7.2.3 BY THERAPEUTIC AREA, 2026-2035 (USD Billion)
      4. 7.2.4 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

China Anti Hypertensive Drugs Market Segmentation

China Anti Hypertensive Drugs Market By Drug Class (USD Billion, 2022-2035)

  • Angiotensin Converting Enzyme Inhibitors
  • Angiotensin II Receptor Blockers
  • Calcium Channel Blockers
  • Diuretics
  • Beta Blockers

China Anti Hypertensive Drugs Market By Administration Route (USD Billion, 2022-2035)

  • Oral
  • Intravenous
  • Subcutaneous
  • Transdermal

China Anti Hypertensive Drugs Market By Therapeutic Area (USD Billion, 2022-2035)

  • Hypertension
  • Heart Failure
  • Chronic Kidney Disease
  • Diabetes

China Anti Hypertensive Drugs Market By Patient Demographics (USD Billion, 2022-2035)

  • Elderly
  • Adults
  • Pediatric
  • Pregnant Women

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.